peripheral blood CD34-positive cells for chronic stroke

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09194
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Foundation for Biomedical Research and Innovation at Kobe
• Principal Investigator: Saino Orie 公益財団法人神戸医療産業都市推進機構, 先端医療研究センター脳循環代謝研究部, 研究員 (90895111)
• Co-Investigator(Kenkyū-buntansha): 小川 優子 公益財団法人神戸医療産業都市推進機構, その他部局等, 研究員 (00454497)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 慢性期脳梗塞 / 造血幹細胞治療 / 再生医療 / 動脈内投与

Outline of Final Research Achievements

There is no treatment for chronic cerebral infarction other than rehabilitation, and the development of new treatments is urgently needed. We have previously revealed that the mechanism of hematopoietic stem cell therapy for subacute cerebral infarction is the supply of energy to damaged vascular endothelial cells via gap junctions, and in this study, we conducted a detailed investigation of hematopoietic stem cell therapy for chronic cerebral infarction. As a result, it was revealed that substances are supplied via gap junctions to not only the damaged side but also the healthy side of the brain tissue, causing metabolic changes and changing synapses, thereby improving neural function. However, there was no change in the number of blood vessels after treatment, making it clear that this is a different mechanism from acute treatment that acts on damaged blood vessels.

Free Research Field

脳梗塞

Academic Significance and Societal Importance of the Research Achievements

慢性期脳梗塞の新規治療法開発が待たれる中、本研究により造血幹細胞治療メカニズムの一端が明らかになったことで実用化の実現へ一歩近づき、社会的意義は大きい。また治療メカニズムの解明は、造血幹細胞を他の疾患治療へ応用する際に大いに役立つと考えられ、学術的意義も深い。